Search Results
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection. Learn more Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979)
More news about: Eli Lilly and Company
Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
disease.10,11,12,13 ICOTYDE™ INDICATION AND IMPORTANT SAFETY INFORMATIONWHAT IS ICOTYDE™ (icotrokinra)?ICOTYDETM 200 mg is a prescription medicine used to treat moderate to severe plaque psoriasis in adults and children 12 years of age and older who weigh at least 88 pounds
More news about: Johnson & Johnson
Mar 27, 2026, 10:44 ET Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
Full Prescribing Information.About LEQSELVI™LEQSELVI (deuruxolitinib) 8 mg tablets is an oral selective inhibitor of Janus kinases JAK1 and JAK2 approved for the treatment of adults with severe alopecia areata. Alopecia areata
More news about: Sun Pharma
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
healthcare provider tells you to use it.SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.About RINVOQ®
More news about: AbbVie
Mar 27, 2026, 09:57 ET /C O R R E C T I O N -- Spinogenix/
schizophrenia to evaluate the safety, efficacy, tolerability and pharmacodynamics of tazbentetol. Enrolled patients received a daily oral dose of 300mg tazbentetol or placebo for six weeks.Results from the prespecified interim analysis of 16 participants presented today at the Schizophrenia International
More news about: Spinogenix
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
therapies.8 EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or
More news about: Eli Lilly and Company
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
patients were randomized to BIMZELX 320mg every 4 weeks (Q4W) or ustekinumab 45/90mg (≤100kg/>100kg) at Week 0, Week 4, then Q12W.3 In BE RADIANT, patients were randomized to BIMZELX Q4W to Week 16, then Q4W or Q8W thereafter, or secukinumab 300mg weekly to Week 4 then Q4W;4
More news about: UCB
Mar 27, 2026, 09:00 ET UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
& II studies could enroll in BE HEARD EXT and receive open-label BIMZELX (BKZ) 320 mg every 2 weeks (Q2W) or Q4W based on HiSCR90 response averaged from Weeks 36, 40, and 44.5 Patients receiving BKZ 320 mg Q4W in BE HEARD EXT who could not sustain an average improvement from baseline in AN
More news about: UCB
Mar 27, 2026, 08:39 ET Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
efficacy in advanced NSCLC and potent antitumor activity in preclinical models of EGFR PACC-mutant tumors. At the recommended phase 3 dose (RP3D) of 300 mg, ZEGFROVY monotherapy demonstrated promising antitumor activity and a manageable safety profile in treatment-naïve patients with advanced NSCLC harboring
More news about: Dizal
Mar 27, 2026, 07:30 ET Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge
hepatorenal syndrome with rapid reduction in kidney function.LIMITATION OF USEPatients with a serum creatinine >5 mg/dL are unlikely to experience benefit.IMPORTANT SAFETY INFORMATIONWARNING: SERIOUS OR FATAL RESPIRATORY FAILURE
More news about: Keenova Therapeutics
Mar 27, 2026, 01:28 ET Updated Cholesterol Guideline Shifts Focus to Lifelong Prevention
below 100 milligrams per deciliter (mg/dL). For those with diabetes, a high chance of developing heart disease, or other risk factors, the goal is below 70 mg/dL. People who have already had a heart attack or stroke are advised to maintain even lower levels—below 55 mg/dL—to help prevent future events.If
More news about: NYU Langone Health
Mar 26, 2026, 16:05 ET Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.; Eisai Co., Ltd
Mar 26, 2026, 15:17 ET От BFA миру: M&G отмечает 20-летие истории канцелярских товаров в Китае
View original content:https://www.prnewswire.com/news-releases/-bfa--mg--20-------302726679.html
More news about: Shanghai M&G Stationery Inc. (M&G)
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
potential for extended dosing intervals. Notably, 50% of patients in the 300 mg group achieved EASI-75 at Week 6 post-first dose, compared to 7% in the placebo group. At Week 12, EASI-75 and EASI-90 response rates in the 300 mg dose group reached 58.3% and 41.7%, respectively, versus 21.4% and 0% in the
More news about: Keymed
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
Domestic supply launchedFollowing the 2024 China NMPA approval for localization production, domestic supply of avapritinib tablets (300 mg and 100 mg) commenced in February 2025, driving anticipated gross margin expansion.NRDL renewalFollowing its initial inclusion
More news about: CStone Pharmaceuticals
Mar 26, 2026, 08:53 ET CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
(TNBC), and hepatocellular carcinoma (HCC).1. Monotherapy Shows Striking Efficacy in First-line NSCLC:CS2009 monotherapy (20 mg/30 mg, Q3W) achieved an ORR of 90% (9/10) and a DCR of 100% (10/10) in first-line NSCLC patients with PD-L1 TPS≥50% (n=10).2. Combination Therapies
More news about: CStone Pharmaceuticals
Mar 26, 2026, 08:31 ET MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned Phase 1 Part 3 16-Week Titration Study to Evaluate 48 mg (1-Step) and 64 mg (2-Step) Regimen Receives
More news about: MetaVia Inc.
Mar 26, 2026, 08:30 ET Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic
More news about: Neurocrine Biosciences, Inc.
Mar 26, 2026, 08:27 ET DermTech 2.0 Further Expands DermTech Stratum with Clinical Trial Support Services
Smart Sticker® provides a 19mm collection area for lesional and non-lesional samples, collecting approximately 1.5mg of representative stratum corneum tissue, eliminating the need for often hard to obtain surgical biopsies in clinical research studies. Once collected,
More news about: DermTech LLC
Mar 26, 2026, 07:05 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
kg/m2) or who are overweight (BMI ≥27 kg/m2). Enrolled patients have been randomized to one of four weekly treatment arms: VK2735 7.5 mg, 12.5 mg, 17.5 mg, and placebo. The primary endpoint of the trial is the percent change in body weight from baseline for participants receiving VK2735 as
More news about: Viking Therapeutics, Inc.
Mar 26, 2026, 06:17 ET VIVATECH UNVEILS THE TOP 30 OF THE 5TH EDITION OF THE AFRICATECH AWARD 2026: NIGERIA, KENYA AND EGYPT ARE THE THREE MOST REPRESENTED COUNTRIES
projects.Finally, 50% of the selected startups are founded or co-founded by women, such as 10mg Health, IFunza and
More news about: VivaTech
Mar 26, 2026, 06:17 ET VIVATECH DÉVOILE LE TOP 30 DE LA 5EME ÉDITION DE L'AFRICATECH AWARD 2026 : NIGERIA, KENYA ET ÉGYPTE SONT LES TROIS PAYS LES PLUS REPRÉSENTÉS
50 % des startups sélectionnées sont fondées ou cofondées par des femmes, comme 10mg Health, IFunza ou
More news about: VivaTech
Mar 26, 2026, 06:00 ET Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
and GLOW2GLOW1 and GLOW2 were prospective, randomized, double-masked, sham-controlled, multicenter Phase 3 studies evaluating Zenkuda 5mg in participants with diabetic retinopathy. Both studies employed extended-interval dosing regimens with an ultimate treatment interval of every six months.
More news about: Kodiak Sciences Inc.
Mar 26, 2026, 00:30 ET World of Wines, Tonique, The Liquor Fort, Hedonne, and House of Spirits are the top beverage retailers in 2026, according to IDRA
Hedonne, Kolkata; Tonique, Kalyani Nagar, Pune; and The Liquor Mart, Malviya Nagar, Jaipur, were among those that continued to hold their ground. Tonique, MG Road also continued to lead in Bengaluru, while World of Wines topped the Mumbai rankings and ranked No. 1 in Goa. Other city leaders included House
More news about: India Drinks Retail Awards (IDRA)
Mar 25, 2026, 20:13 ET Dari BFA hingga Mendunia: M&G Memasok Alat Tulis dan Kantor Buatan Tiongkok Selama 20 Tahun
multimedia:https://www.prnewswire.com/id/rilis-berita/dari-bfa-hingga-mendunia-mg-memasok-alat-tulis-dan-kantor-buatan-tiongkok-selama-20-tahun-302725494.htmlSOURCE
More news about: Shanghai M&G Stationery Inc. (M&G)